HCPCS Level II J0178: Aflibercept Injection, 1 mg
HCPCS Level II code J0178 describes an injection of aflibercept, 1 mg, administered as an intravitreal pharmacologic agent for ophthalmic conditions; the service is a drug administration procedure typically performed in an office or outpatient ophthalmology clinic setting during an intravitreal injection visit.
For related coverage guidance, see recent payer policy updates: Epithelial Cell Cytology in Breast Cancer Risk Assessment, Chemotherapy Observation or Inpatient Hospitalization (for New Mexico Only), Umbilical Cord Blood Harvesting and Storage for Future Use (for Indiana Only).
Customize your policy alerts
Sign up for hcpcs J0178 policy alerts
Get alerted when payer policies referencing J0178 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
National commercial rates for HCPCS J0178 cluster around BUCA’s average commercial rate of $906.40, with several major payers near that midpoint but meaningful variation at the top end. Blue Cross Blue Shield’s median is close to its 25th–75th band around $843.60–$928.40, while Cigna and UnitedHealth Group have medians at $771.60 and similar upper quartiles near $819.00 and $831.90 respectively. Aetna exhibits the broadest spread and highest ceiling, with a 25th percentile at $442.90 and a 75th percentile at $1,724.60, producing a wide interquartile swing.
Measuring dispersion as P75 minus P25 highlights where rates are tightest or widest: Blue Cross Blue Shield’s interquartile range is $90.80, Cigna’s is $47.40, and UnitedHealth Group’s is $60.90, indicating relatively tight clustering. BUCA’s quartiles span $765.80 to $1,012.70 (IQR $246.90), while Aetna’s IQR is $1,281.70, the widest by far and reflecting substantial upper-end leverage compared with other commercial payers.